{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:28:44Z","timestamp":1781306924092,"version":"3.54.1"},"reference-count":8,"publisher":"American Society for Microbiology","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The goal of this study was to compare the BioPlex 2200 measles, mumps, rubella, and varicella-zoster virus (MMRV) IgG multiplex assays (Bio-Rad Laboratories, Hercules, CA) to routine testing by enzyme immunoassay (EIA). Serum specimens (<jats:italic>n<\/jats:italic>= 500) submitted to our reference laboratory for routine MMRV IgG testing by EIA were also tested by the BioPlex assays. Following testing, the BioPlex measles, mumps, rubella, and varicella-zoster virus assays demonstrated agreements of 91.6% (95% confidence interval [CI], 88.8% to 93.7%), 94.2% (95% CI, 91.7% to 95.7%), 94.4% (95% CI, 92.0% to 96.1%), and 91.8% (95% CI, 89.0% to 93.9%), respectively, compared to the results of EIA. Timing studies showed that the BioPlex MMRV assay could provide complete analysis of 100 serum specimens in 1.7 h, compared to 5.5 h by EIA. These data indicate that the BioPlex MMRV IgG assays exhibit comparable performance (93% overall agreement [1,860\/2,000 results]; \u03ba = 0.67) to routine testing by EIA. The BioPlex assays allow for the simultaneous detection of all four analytes, thereby eliminating potential aliquot errors and reducing turnaround time.<\/jats:p>","DOI":"10.1128\/cvi.05207-11","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T04:10:42Z","timestamp":1311826242000},"page":"1524-1526","source":"Crossref","is-referenced-by-count":30,"title":["Evaluation of the Bio-Rad BioPlex Measles, Mumps, Rubella, and Varicella-Zoster Virus IgG Multiplex Bead Immunoassay"],"prefix":"10.1128","volume":"18","author":[{"given":"Matthew J.","family":"Binnicker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Jespersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard O.","family":"Rollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","published-online":{"date-parts":[[2011,7,27]]},"reference":[{"key":"key20180919073531_B1","doi-asserted-by":"crossref","first-page":"6504","DOI":"10.1016\/j.vaccine.2009.07.076","article-title":"A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile","volume":"27","author":"Czajka","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073531_B2","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/ije\/dyn261","article-title":"Ongoing measles and rubella transmission in Georgia, 2004-05: implications for the national and regional elimination efforts","volume":"38","author":"Doshi","year":"2009","journal-title":"Int. J. Epidemiol."},{"key":"key20180919073531_B3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jaci.2006.07.033","article-title":"Mumps resurgence in the United States","volume":"118","author":"Kancherla","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"key20180919073531_B4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","article-title":"The measurement of observer agreement for categorical data","volume":"33","author":"Landis","year":"1977","journal-title":"Biometrics"},{"key":"key20180919073531_B5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMp068149","article-title":"Measles in the United States, 2006","volume":"355","author":"Mulholland","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"key20180919073531_B6","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/INF.0b013e318170bb22","article-title":"Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life","volume":"27","author":"Schuster","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"key20180919073531_B7","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.25011\/cim.v32i1.5086","article-title":"Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in western region of Turkey","volume":"32","author":"Tamer","year":"2009","journal-title":"Clin. Invest. Med."},{"key":"key20180919073531_B8","first-page":"241","article-title":"Varicella vaccines. WHO position paper","volume":"73","author":"WHO","year":"1998","journal-title":"Wkly. Epidemiol. Rec."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.05207-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:45:49Z","timestamp":1627591549000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.05207-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":8,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,8,31]]},"published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1128\/CVI.05207-11"],"URL":"https:\/\/doi.org\/10.1128\/cvi.05207-11","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}